Barclays has adjusted its price target for Blackstone Inc. (BX), lowering it from $164 to $126, while retaining an 'Equal Weight' rating. This recalibration is based on revised projections for the alternative asset management sector, taking into account the anticipated influence of artificial intelligence on portfolio companies and a reduction in earnings expectations tied to business development companies. Concurrently, Blackstone's Life Sciences division has embarked on a collaborative funding initiative with Johnson & Johnson, focusing on advancing the clinical development of bleximenib, a drug targeting acute myeloid leukemia.
On March 2, Barclays announced its decision to lower the price target for Blackstone Inc. (NYSE:BX), revising it down from $164 to $126. The financial institution maintained an 'Equal Weight' recommendation for the stock. This adjustment stemmed from a comprehensive re-evaluation of estimates across the entire alternative asset manager industry. Analysts noted that it remains premature to fully ascertain the comprehensive impact of artificial intelligence on portfolio companies. Additionally, the firm cited reduced expectations for earnings associated with business development companies, attributing this to lower flow assumptions and the timing of asset realizations.
Further noteworthy developments for Blackstone Inc. (NYSE:BX) include an announcement on February 23 by Blackstone Life Sciences (BXLS) regarding a research and development funding agreement. This agreement is designed to expedite the clinical progression of bleximenib, an oral menin inhibitor currently under investigation for the treatment of acute myeloid leukemia (AML). Management underscored the critical need for new treatments, highlighting that AML, despite being the most prevalent acute leukemia in adults, continues to present significant therapeutic challenges and is characterized by the lowest survival rates among all leukemia types.
In a significant collaborative effort, Blackstone Inc. (NYSE:BX) confirmed that Johnson & Johnson, alongside funds overseen by BXLS, would jointly finance a portion of both ongoing and prospective clinical trials for bleximenib in AML. This partnership marks a pioneering co-funding arrangement between BXLS and Johnson & Johnson, signaling a shared commitment to addressing this aggressive form of cancer. Blackstone Inc. offers a diverse range of investment and fund management services, structured across several key segments: Real Estate, Private Equity, Credit and Insurance, and Hedge Fund Solutions.
Despite acknowledging the inherent investment potential of BX, certain AI-focused stocks are believed to offer more substantial upside and mitigated downside risks. These opportunities are particularly compelling for those seeking deeply undervalued AI equities that are also poised to gain significantly from prevailing economic trends such as Trump-era tariffs and the growing impetus for domestic manufacturing and reshoring initiatives. Investors interested in these specific, high-potential AI stocks are encouraged to explore specialized reports detailing such investment prospects.